These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10500605)

  • 1. Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients.
    Vila A; Guirado LL; Balius A; Díaz M; Baró E; Olaya M; Andrade M; Agraz I; Solá R
    Transplant Proc; 1999 Sep; 31(6):2335-6. PubMed ID: 10500605
    [No Abstract]   [Full Text] [Related]  

  • 2. Superior efficacy of oral ganciclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients.
    Somerville T; Hurst G; Alloway R; Gaber A; Shokouh-Amiri MH; Stratta R
    Transplant Proc; 1998 Jun; 30(4):1546-8. PubMed ID: 9636628
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits.
    Bertoni E; Rosati A; Zanazzi M; Moscarelli L; Di Maria L; Piperno R; Orsi A; Parri F; Dedola G; Salvadori M
    Transplant Proc; 1998 Aug; 30(5):2094. PubMed ID: 9723402
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary?
    Smith SR; Butterly DW; Conlon PJ; Harland RC; Emovon OE
    Transplant Proc; 1998 Aug; 30(5):2097-9. PubMed ID: 9723404
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
    Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation.
    Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD
    Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganciclovir for cytomegalovirus infection in renal transplant recipients.
    Lancet; 1989 Jan; 1(8631):216-7. PubMed ID: 2563118
    [No Abstract]   [Full Text] [Related]  

  • 10. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis.
    Opelz G; Daniel V; Naujokat C; Fickenscher H; Döhler B
    Lancet Oncol; 2007 Mar; 8(3):212-8. PubMed ID: 17329191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients.
    Jorgenson MR; Descourouez JL; Leverson GE; McCreary EK; Lucey MR; Smith JA; Redfield RR
    Ann Pharmacother; 2018 Jan; 52(1):5-10. PubMed ID: 28844151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
    Uber L; Cofer J; Baliga P; Rajagopalan PR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
    [No Abstract]   [Full Text] [Related]  

  • 16. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
    Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
    Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
    Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
    Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
    Kır O; Zeytinoğlu A; Arda B; Yılmaz M; Aşçı G; Töz H
    Transplant Proc; 2017 Apr; 49(3):537-540. PubMed ID: 28340829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.